Navigation Links
Lilly CEO Says Industry, Public Policy Must Pave Way For Innovation
Date:2/10/2011

LONDON, Feb. 10, 2011 /PRNewswire/ -- A new approach to research, along with public policies that support medical innovation, will help biopharmaceutical companies address stubborn diseases with potentially devastating personal and financial consequences, such as cancer and Alzheimer's disease, according to John Lechleiter, Ph.D., chairman, president and CEO of Eli Lilly and Company (NYSE: LLY).

Lechleiter made his remarks Thursday in London during a keynote address at The Economist's 2011 Pharma Summit: Reinventing Pharma for a New Generation. During his talk, Lechleiter said two imperatives are needed to secure the future of the research-based pharmaceutical industry: changing the way companies conduct research, and public policies that promote an environment in which medical innovation can flourish.

The burden of several diseases is soaring in many countries, including the U.K.

According to the Alzheimer's Research Trust, for instance, more than 800,000 people in the U.K. are directly affected by dementia at a cost of 23 billion pounds Sterling per year.

And yet, just when the world desperately needs more new medicines for diseases like Alzheimer's, "our industry is taking too long, we're spending too much, and we're producing far too little," Lechleiter told the audience.

Lechleiter said the case for biopharmaceutical research and new medications is compelling. Specifically, he noted that:

  • Innovative medicines have proven themselves time and again to be the most effective way to reduce costs and improve quality in health care.
  • Treatments for diseases that remain unconquered, like cancer and Alzheimer's, most likely will come from laboratories of biopharmaceutical companies.
  • Even diseases that are being treated today, like diabetes, require better solutions.

"Ironically, the crisis in our innovation model comes at a time when we have vastly more s
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lilly and the Juvenile Diabetes Research Foundation Partner to Fund Regenerative Medicine Research in Type 1 Diabetes
2. Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab
3. Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance
4. Statement from Lilly and Avid on FDA Advisory Committee Recommendation for Amyvid™ (Florbetapir) NDA
5. Cognizant Selected by Lilly to Deliver Commercial Operations Solutions to Enhance Sales and Marketing Effectiveness, Business Performance
6. Lilly Confirms Date and Conference Call for Fourth-Quarter and Full-Year 2010 Financial Results Announcement
7. Statement From Lilly on FDA Advisory Committee Recommendation Regarding Liprotamase New Drug Application for Treatment of Exocrine Pancreatic Insufficiency
8. Lilly Announces Completion of Avid Acquisition and FDA Priority Review for florbetapir
9. Manchester College Receives $35 Million Grant From Lilly Endowment for School of Pharmacy
10. Lilly Statement Regarding President Obamas Meeting With U.S. Business Leaders
11. Lilly Suspends Phase III Trial in Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014  The law firm McElroy, Deutsch, Mulvaney ... will serve as host for "Show Me the ... of Healthcare Reform," a one-day conference scheduled for ... reimbursement, compliance and enforcement in a marketplace re-shaped ... Logo -  http://photos.prnewswire.com/prnh/20140916/146606 Logo -  http://photos.prnewswire.com/prnh/20140916/146607 ...
(Date:9/17/2014)... , Sept. 17, 2014   GS1 ... how to implement GS1 Standards to support the ... enhance patient safety and security in the pharmaceutical ... GS1 Standards to U.S. Pharmaceutical Supply Chain Business ... Act , was developed in collaboration with ...
(Date:9/17/2014)... 2014 Sutro Biopharma, a biopharmaceutical company developing ... division of Merck KGaA, Darmstadt, Germany ... the United States and Canada ... to develop antibody drug conjugates (ADCs). ADCs are composed ... antibody is thought to specifically target and deliver the ...
Breaking Medicine Technology:Three Leading Healthcare Organizations Sponsor Conference to Examine Opportunities and Risks of Healthcare Reform for Providers 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 3New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 4Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 2Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 3Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 4
... 13, 2011 ULURU Inc. (NYSE AMEX: ... of intent with Melmed Holdings AG, a company based in Switzerland, ... terms of the agreement ULURU will license the European Union rights ... Altrazeal® in the European Union. In exchange for the license ULURU ...
... Mass., Oct. 12, 2011 NxStage Medical, Inc. (Nasdaq: ... dialysis products, today announced plans to release its financial ... on Thursday, November 3, 2011 before the opening of ... NxStage will also host a conference call at 9:00 ...
Cached Medicine Technology:ULURU Inc. Announces Altrazeal® Agreement for the European Market 2ULURU Inc. Announces Altrazeal® Agreement for the European Market 3NxStage® to Report Third Quarter Fiscal 2011 Financial Results 2
(Date:9/17/2014)... (PRWEB) September 18, 2014 Recently, UWDress.com, ... dresses and women’s special occasion outfits, has released its ... In addition, the firm has launched a big sale ... are now available at deeply discounted rates, from 15 ... that the company insists on using comfortable to wear ...
(Date:9/17/2014)... 2014 According to Centers for ... an estimated 173,285 sports- and recreation-related traumatic brain injuries, ... a blood test may be available to help doctors ... recovery will take. , In March of this ... found a way to test blood for a protein ...
(Date:9/17/2014)... According to an August 5, ... “Adverse Events Associated with Use of Enhancement Medical's ... use of Expression, a hyaluronic acid product, for ... including discoloration, lumps, bruising, nodules, and swelling. ... cosmetic use include Restylane , Juvéderm, Perlane, ...
(Date:9/17/2014)... 2014 Final Cut Pro X plugin developers ... from Pixel Film Studios. , “ProBlue 5k is a compilation ... good to epic,” said Christina Austin, CEO of Pixel Film ... is a definite game changer.” , ProBlue 5k is the ... filmmaker ! This footage compilation of over 100 anamorphic ...
(Date:9/17/2014)... People who struggle to distinguish between a business strategy ... and get the answer by reading Per Wickstrom’s latest blog ... a business plan and a business strategy are both strategic ... “The way I view it is that a business plan ... part two.” , According to the blog post, a ...
Breaking Medicine News(10 mins):Health News:2014 Empire Waist Evening Dress Collection Now Unveiled At UWDress.com 2Health News:Breakthrough blood test will improve concussion diagnoses, treatment 2Health News:Breakthrough blood test will improve concussion diagnoses, treatment 3Health News:Simon Ourian, Kim Kardashian's Cosmetic Surgeon, Warns About Illegal Use of Expression as a Dermal Filler 2Health News:A New Plugin Entitled ProBlue 5k Was Released Today from Pixel Film Studios Exclusively for Final Cut Pro X 2Health News:Per Wickstrom’s Latest Blog Explores the Difference Between a Business Plan and a Business Strategy 2
... ... , ... April 19, 2010 -- ORCS Web Inc., a specialist in Microsoft Windows-based internet hosting ... newly released ASP .NET 4.0 has been made available on all of their ...
... ... to age gracefully and maintain healthy skin? Here are 35 articles that cover the full ... any age, makeup tips for mature skin and the details on effective ingredients. , ... (PRWEB) April 19, 2010 -- Aging ...
... ... Institute is penetrating major metropolitan areas with its high-demand, proactive medical approach that optimizes ... ... Medical Institute , global age management medicine leader, is meeting the healthy aging boom ...
... ... the 40th Earth Day. The first Earth Day was held in 1970 and is widely seen ... ... join the worldwide community in celebrating the 40th Earth Day. The first Earth Day was held ...
... at the Medical College of Wisconsin and Children,s Hospital ... have found that many metropolitan Milwaukee child care directors ... Andrew N. Hashikawa, M.D., and colleagues surveyed 305 child ... directors followed national guidelines from the American Academy of ...
... Treatment may be used one day as part of cancer-fighting ... April 18 (HealthDay News) -- A new study in mice ... cells could become a target for cancer vaccines. , A ... transcription) of genetic material from the DNA to messenger RNA. ...
Cached Medicine News:Health News:ORCS Web, Inc Supports ASP .NET 4.0 2Health News:Anti-Aging Handbook: Top 35 Articles on Treating and Preventing Signs of Aging 2Health News:Anti-Aging Handbook: Top 35 Articles on Treating and Preventing Signs of Aging 3Health News:Anti-Aging Handbook: Top 35 Articles on Treating and Preventing Signs of Aging 4Health News:Global Leader Readied For Healthy Aging Boom, Targets Wall Street With New Center In Trump Building 2Health News:Global Leader Readied For Healthy Aging Boom, Targets Wall Street With New Center In Trump Building 3Health News:Global Leader Readied For Healthy Aging Boom, Targets Wall Street With New Center In Trump Building 4Health News:Ecco Bella, A Natural Beauty and Skin Care Company, Celebrates Earth Day 2010 2Health News:Day care dilemma: When 'sick' children are unnecessarily sent home 2Health News:Vaccine Stops Tumor Spread in Mice 2
Sealing tape, white Rayon, breathable, NS...
Amplification Tape 96 featuring 3M adhesive technology. Good optical quality. Minimal autofluorescence. Certified RNase and DNase free....
Sealing tape featuring 3M adhesive technology. Compatible with DMSO. Good optical quality. Minimal autofluorescence....
Thermal Seal, Clear, Bulk...
Medicine Products: